TAGBIKO
LIVE

Serial Number

99852895

Owner

BeOne Medicines I GmbH

Attorney

Kristen Ruisi

Filing Date

May 29, 2026

Add to watchlist:

No watchlists yet
View on USPTO

TAGBIKO Trademark

Serial Number: 99852895

TAGBIKO is a trademark filed by BeOne Medicines I GmbH on May 29, 2026. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

BeOne Medicines I GmbH (74 trademarks)

Aeschengraben 27
Basel 4051 , CH

Entity Type: 27

Trademark Details

Filing Date

May 29, 2026

Registration Date

Not Registered

Published for Opposition

July 21, 2026

Goods & Services

Medicines for human purposes for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemico-pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; drugs for medical use being medicines for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological preparations for medical use for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for pharmaceutical use, namely, for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for medical use, namely, for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; injectable pharmaceuticals for treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; crude medicines for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biochemical preparations for medical use, namely, the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases

Filing History

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 21, 2026 NPUB
PUBLISHED FOR OPPOSITION
Jul 21, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 15, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 23, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 22, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 22, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 22, 2026 TROA
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Jun 22, 2026 GEAN
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Jun 22, 2026 GEAP
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
Jun 22, 2026 EPEN
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Jun 22, 2026 CPEA
ASSIGNED TO EXAMINER
Jun 17, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
May 29, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 29, 2026 NWOS
NEW APPLICATION ENTERED
May 29, 2026 NWAP